Noble Financial reaffirmed their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report published on Sunday morning.

A number of other equities research analysts also recently weighed in on HRTX. BidaskClub downgraded shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Friday, August 18th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a research note on Friday, August 18th. Zacks Investment Research raised shares of Heron Therapeutics from a sell rating to a hold rating in a research note on Wednesday, November 8th. Mizuho reaffirmed a buy rating and issued a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Jefferies Group LLC reaffirmed a buy rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of Buy and an average price target of $28.36.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at $15.45 on Friday. Heron Therapeutics has a fifty-two week low of $12.21 and a fifty-two week high of $20.85. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.10. The business had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. research analysts expect that Heron Therapeutics will post -3.41 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2017/11/15/heron-therapeutics-inc-hrtx-earns-buy-rating-from-noble-financial.html.

Several hedge funds have recently bought and sold shares of HRTX. Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 27.1% during the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock worth $2,861,000 after acquiring an additional 40,657 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Heron Therapeutics by 86.8% during the first quarter. Parametric Portfolio Associates LLC now owns 33,139 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 15,394 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 2.8% during the first quarter. JPMorgan Chase & Co. now owns 69,352 shares of the biotechnology company’s stock worth $1,041,000 after acquiring an additional 1,897 shares in the last quarter. American International Group Inc. raised its stake in shares of Heron Therapeutics by 38.6% during the first quarter. American International Group Inc. now owns 25,332 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 7,059 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Heron Therapeutics by 14.4% during the first quarter. Alliancebernstein L.P. now owns 55,700 shares of the biotechnology company’s stock worth $836,000 after acquiring an additional 7,000 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.